DYG Versus Cetrorelix in Oocyte Donation

Clinica de la Mujer Medicina Reproductiva, Chile

Status: Completed

Conditions: Fertility Disorders; Infertility, Female

Treatments: Drug: Dydrogesterone

Study type: Observational

Funder types: Other

Identifiers

NCT05577806

PPOS-DU-OD

Details and patient eligibility

About

Prospective controlled study to assess the reproductive outcomes of OD recipients in which the donors were subjected to the DYG protocol (20mg/day) compared with those subjected to the short protocol with cetrorelix (0.25 mg/day) from Day 7 or since a leading follicle reached 14 mm. The OD cycles were triggered with triptoreline acetate and the trigger criterion was ≥3 follicles of diameter >18mm.

Enrollment: 202 estimated patients

Sex: Female

Ages: 21 to 30 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Oocyte donors between 21 and 30 years old, with regular menstrual cycles (24-35 d) and a body mass index (BMI) between 18 and 28 kg/m2 without any relevant personal or family history

Exclusion criteria

• AMH less than 3 ng/dL
• A positive screening for sexually transmitted diseases

Trial design

202 participants in 2 patient groups

DYG

Description:

oocyte donors undergoing controlled ovarian stimulation in a progestin-primed ovarian stimulation protocol with DYG protocol (20mg/day)

Treatment:

Drug: Dydrogesterone

Cetrorelix

Description:

oocyte donors undergoing controlled ovarian stimulation in a GnRH antagonist protocol with cetrorelix (0.25 mg/day) from Day 7 or since a leading follicle reached 14 mm